Bridget E. Bunner

Array ( [id] => 16558414 [patent_doc_number] => 20210003563 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-07 [patent_title] => PATIENT-SPECIFIC CANCER THERAPY SCREENING AND METHODS OF TREATMENT [patent_app_type] => utility [patent_app_number] => 16/875910 [patent_app_country] => US [patent_app_date] => 2020-05-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13854 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16875910 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16267306 [patent_doc_number] => 20200268793 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-27 [patent_title] => METHODS AND COMPOSITIONS FOR ALLEVIATING CYTOKINE RELEASE SYNDROME [patent_app_type] => utility [patent_app_number] => 15/931027 [patent_app_country] => US [patent_app_date] => 2020-05-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32818 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -33 [patent_words_short_claim] => 8 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15931027 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16267306 [patent_doc_number] => 20200268793 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-27 [patent_title] => METHODS AND COMPOSITIONS FOR ALLEVIATING CYTOKINE RELEASE SYNDROME [patent_app_type] => utility [patent_app_number] => 15/931027 [patent_app_country] => US [patent_app_date] => 2020-05-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32818 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -33 [patent_words_short_claim] => 8 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15931027 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16267306 [patent_doc_number] => 20200268793 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-27 [patent_title] => METHODS AND COMPOSITIONS FOR ALLEVIATING CYTOKINE RELEASE SYNDROME [patent_app_type] => utility [patent_app_number] => 15/931027 [patent_app_country] => US [patent_app_date] => 2020-05-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32818 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -33 [patent_words_short_claim] => 8 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15931027 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18504674 [patent_doc_number] => 11702479 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-07-18 [patent_title] => Anti-jagged antibodies and methods of use [patent_app_type] => utility [patent_app_number] => 16/872631 [patent_app_country] => US [patent_app_date] => 2020-05-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 36 [patent_figures_cnt] => 41 [patent_no_of_words] => 24841 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 124 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16872631 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16312371 [patent_doc_number] => 20200291109 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-17 [patent_title] => Composition to induce bone marrow stem cell mobilization [patent_app_type] => utility [patent_app_number] => 16/870981 [patent_app_country] => US [patent_app_date] => 2020-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6458 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 103 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16870981 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16570665 [patent_doc_number] => 20210009671 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-14 [patent_title] => COMPOUNDS AND METHODS FOR TREATING PAIN [patent_app_type] => utility [patent_app_number] => 16/868590 [patent_app_country] => US [patent_app_date] => 2020-05-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26835 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16868590 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16391061 [patent_doc_number] => 20200332002 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-22 [patent_title] => ANTIBODY CONSTRUCTS FOR DLL3 AND CD3 [patent_app_type] => utility [patent_app_number] => 16/868257 [patent_app_country] => US [patent_app_date] => 2020-05-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50746 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16868257 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17859809 [patent_doc_number] => 11440954 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-09-13 [patent_title] => Optimized anti-TL1A antibodies [patent_app_type] => utility [patent_app_number] => 16/863971 [patent_app_country] => US [patent_app_date] => 2020-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 49 [patent_no_of_words] => 38311 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 165 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16863971 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16267363 [patent_doc_number] => 20200268850 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-27 [patent_title] => METHODS AND COMPOSITIONS FOR MOBILIZING STEM CELLS [patent_app_type] => utility [patent_app_number] => 16/849950 [patent_app_country] => US [patent_app_date] => 2020-04-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41616 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16849950 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16376368 [patent_doc_number] => 20200325210 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-15 [patent_title] => CYSTEINE ENGINEERED FIBRONECTIN TYPE III DOMAIN BINDING MOLECULES [patent_app_type] => utility [patent_app_number] => 16/840479 [patent_app_country] => US [patent_app_date] => 2020-04-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34905 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16840479 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17685840 [patent_doc_number] => 20220193132 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-23 [patent_title] => ANTI-EGFRVIII ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS THEREOF [patent_app_type] => utility [patent_app_number] => 17/441708 [patent_app_country] => US [patent_app_date] => 2020-03-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26641 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -45 [patent_words_short_claim] => 148 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17441708 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16312349 [patent_doc_number] => 20200291087 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-17 [patent_title] => ANTI-BCMA CHIMERIC ANTIGEN RECEPTORS [patent_app_type] => utility [patent_app_number] => 16/825996 [patent_app_country] => US [patent_app_date] => 2020-03-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32900 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16825996 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16621527 [patent_doc_number] => 20210040180 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-11 [patent_title] => CD137 Binding Fibronectin Type III Domains [patent_app_type] => utility [patent_app_number] => 16/820844 [patent_app_country] => US [patent_app_date] => 2020-03-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20296 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16820844 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16361320 [patent_doc_number] => 20200318071 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-08 [patent_title] => GENETICALLY ENGINEERED HEMATOPOIETIC STEM CELLS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/813958 [patent_app_country] => US [patent_app_date] => 2020-03-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 69237 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16813958 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16297772 [patent_doc_number] => 20200283495 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-10 [patent_title] => Chimeric Endocytic Receptors and Method of Use Thereof [patent_app_type] => utility [patent_app_number] => 16/813417 [patent_app_country] => US [patent_app_date] => 2020-03-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6138 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16813417 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17578795 [patent_doc_number] => 20220135650 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-05 [patent_title] => ENGINEERED CD47 EXTRACELLULAR DOMAIN FOR BIOCONJUGATION [patent_app_type] => utility [patent_app_number] => 17/435325 [patent_app_country] => US [patent_app_date] => 2020-03-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14823 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17435325 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16598081 [patent_doc_number] => 20210024612 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-28 [patent_title] => PD-L1 BINDING FIBRONECTIN TYPE III DOMAINS [patent_app_type] => utility [patent_app_number] => 16/801787 [patent_app_country] => US [patent_app_date] => 2020-02-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16836 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16801787 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17563192 [patent_doc_number] => 20220127341 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-28 [patent_title] => A METHOD FOR THE TREATMENT OR PROPHYLAXIS OF CANCER BY TARGETING THE EXTRACELLULAR PORTION OF KERATIN 14 (KRT14) RESIDING ON CANCER CELLS [patent_app_type] => utility [patent_app_number] => 17/429093 [patent_app_country] => US [patent_app_date] => 2020-02-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24589 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -49 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17429093 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17563192 [patent_doc_number] => 20220127341 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-28 [patent_title] => A METHOD FOR THE TREATMENT OR PROPHYLAXIS OF CANCER BY TARGETING THE EXTRACELLULAR PORTION OF KERATIN 14 (KRT14) RESIDING ON CANCER CELLS [patent_app_type] => utility [patent_app_number] => 17/429093 [patent_app_country] => US [patent_app_date] => 2020-02-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24589 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -49 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17429093 [rel_patent_id] =>[rel_patent_doc_number] =>)